

Appl. No. 10/632,187

Amdt. Dated September 21, 2006


Reply to Final Office Action of March 24, 2006

Page 2 of 11


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neases~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II;



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;

R is hydrogen, a linear or branched C₁ to C₂₀ alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups;

R₁, R₂, R₃ independently of one another represent hydrogen, a linear or branched (C₁ to C₆) alkyl group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group,

LIBNY/4549885.1

Appl. No. 10/632,187


Amdt. Dated September 21, 2006

Reply to Final Office Action of March 24, 2006

Page 3 of 11

which may be unsubstituted or optionally substituted at the same or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C₁ to C₆ alkoxy, amino, mono-(C₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups and pharmaceutically acceptable salts and prodrugs thereof; wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 2 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neoses~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound having the structure of Formula I:



Formula I

where, independently of one another,

n is the integer 1 or 2;

m is the integer 1;

x is O;

R is H or a straight-chain or branched (C₁-C₁₇)-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

Appl. No. 10/632,187

Amdt. Dated September 21, 2006


Reply to Final Office Action of March 24, 2006

Page 4 of 11

R_1, R_2, R_3 are, independently of one another, H or a straight-chain or branched (C_1 - C_6)alkyl group, preferably methyl and ethyl, a (C_3 - C_7)-cycloalkyl group;

wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 3 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neases~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula II:



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C_1 - C_{17})-alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

Appl. No. 10/632,187

Amdt. Dated September 21, 2006

Reply to Final Office Action of March 24, 2006

Page 5 of 11

R₁, R₂, R₃ are, independently of one another, H or a straight-chain or branched (C₁-C₆)alkyl group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group;

wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 4 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~enoses~~, wherein the method comprises administering a therapeutically effect amount of octadecyl 1,1-dimethylpiperidinium-4-yl phosphate as claimed in claim 1 wherein said alkylphosphocholine is administered before and/or during treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 5 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~enoses~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, in which the approved antitumor substance is chosen from alkylating agents, antimetabolites, plant alkaloids, platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.

LIBNY/4549885.1

Appl. No. 10/632,187

Amdt. Dated September 21, 2006

Reply to Final Office Action of March 24, 2006

Page 6 of 11

Claim 6 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neoplasms~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, wherein the antitumor substance is chosen from cisplatin, cyclophosphamide or doxorubicin.

Claim 7 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neoplasms~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, in which the approved antitumor substance is chosen from inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.

Claim 8 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neoplasms~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, where the inhibitors are chosen from monoclonal antibodies or heterocyclic compounds.

Claim 9 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~neoplasms~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, ~~in a therapeutic dose which is effective for the treatment~~ before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel,

LIBNY/4549885.1

Appl. No. 10/632,187
Amdt. Dated September 21, 2006
Reply to Final Office Action of March 24, 2006
Page 7 of 11

docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 10 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~eneeses~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the general Formula I or II as claimed in claims 1, 2, 3, or 4, where the approved antitumor substance is a combination of various cytostatics.

Claim 11 (currently amended): A method of treating mammary carcinoma ~~benign and malignant~~ ~~eneeses~~, wherein the method comprises administering a therapeutically effect amount of an alkylphosphocholine compound of the Formula I or II as claimed in claims 1, 2, 3, or 4 wherein said alkylphosphocholine is administered before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin, wherein the drug product comprises the customary pharmaceutical carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I or II.

Claim 12 (currently amended): A drug product consisting essentially of an alkylphosphocholine of the general Formula I or II as in claims 1, 2, 3, or 4 and, where appropriate, carriers and/or excipients for use in the treatment of mammary carcinoma ~~benign and malignant~~ ~~eneeses~~ wherein the drug product is administered before and/or during the treatment with an approved antitumor substance chosen from cis-platinum, carboplatinum,

LIBNY/4549885.1

Appl. No. 10/632,187

Amdt. Dated September 21, 2006

Reply to Final Office Action of March 24, 2006

Page 8 of 11

oxaliplatin, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

LIBNY/4549885.1